Blood cancer
On this page:
The Ottawa Hospital is conducting cutting-edge research to improve our understanding of blood cancer and develop better approaches for treatment and prevention. This page includes selected news stories about our blood cancer research, links to researchers working in this area and related resources. Learn more below.
Research & News
Labs and Groups
These research teams may include multiple scientists, investigators, staff and trainees all working towards a common goal, or they can represent a single scientist and their team.
Ardolino Cancer Immunology Lab
Canadian-Led Immunotherapies Collaborative
Marjorie Brand
Senior Scientist Affiliate, Regenerative Medicine
Clinical Trials
The following list of clinical trials at The Ottawa Hospital is pulled from ClinicalTrials.gov, which is hosted by the U.S. National Library of Medicine and only available in English. If you find a clinical trial that interests you, you can bring the information to the next appointment with your care team and ask if you are eligible for the study. If so, they may be able to refer you to the study team. If you email the study team directly, we can guarantee a response. Learn more about participating in research and clinical trials.
Outpatient and Intermittent Dosing of Elranatamab in Relapsed/Refractory Multiple Myeloma (NCT06421675)
Refractory Multiple Myeloma View DetailsA Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma (NCT06413498)
Multiple Myeloma View DetailsTo Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL (NCT06072131)
Peripheral T Cell Lymphoma View DetailsIbrutinib Combination Therapy in Transplant Ineligible Individuals With Newly Diagnosed Primary CNS Lymphoma (NCT05998642)
Non-hodgkin Lymphoma View DetailsFixed Duration vs Continuous Daratumumab in Transplant Ineligible Older Adults With Newly Diagnosed Multiple Myeloma (NCT06182774)
Multiple Myeloma View DetailsEconomic Analysis of Early vs Delayed Therapy in Newly Diagnosed Asymptomatic High-Risk Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: (NCT05371808)
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma View DetailsPembrolizumab and Brentuximab Vedotin vs GDP and Stem Cell Transplant for Relapsed/Refractory Hodgkin Lymphoma (NCT05180097)
Hodgkin Lymphoma View DetailsEmotion and Symptom-Focused Engagement Trial for Individuals With Acute Leukemia (NCT04224974)
Acute Leukemia View DetailsPhase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation (NCT05243797)
Multiple Myeloma View DetailsCanadian Profiling and Targeted Agent Utilization Trial (CAPTUR) (NCT03297606)
Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid Tumors View DetailsCLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies (NCT06208735)
B-Cell Leukemia, Non-Hodgkin's Lymphoma, B-cell Acute Lymphoblastic Leukemia, Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Primary Mediastinal Large B-cell Lymphoma (PMBCL), Mantle Cell Lymphoma, B-cell Lymphoma View DetailsA Study Comparing Venetoclax and Azacitidine Plus Cusatuzumab to Venetoclax and Azacitidine in Newly Diagnosed AML Ineligible for Intensive Therapy (NCT06384261)
Leukemia, Myeloid, Acute View DetailsQuizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML (NCT06578247)
Leukemia View DetailsA Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma (NCT06084936)
Lymphoma View DetailsA Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma (NCT05827016)
Multiple Myeloma View DetailsA Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma (NCT05730036)
Relapsed Refractory Multiple Myeloma (RRMM) View DetailsCLIC-1901 for the Treatment of Patients With Relapsed/Refractory CD19 Positive Hematologic Malignancies (NCT03765177)
Acute Lymphoblastic Leukemia, Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia View DetailsStudy Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia (NCT04994717)
Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL) View DetailsEfficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003) (NCT04728893)
Hematologic Malignancies, Waldenstroms Macroglobulinaemia, Non-Hodgkins Lymphoma, Chronic Lymphocytic Leukaemia View DetailsA Study to Assess Adverse Events of Intravenously (IV) Infused ABBV-383 in Adult Participants With Relapsed or Refractory Multiple Myeloma (NCT05650632)
Multiple Myeloma View DetailsStudy of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma (NCT06191744)
Follicular Lymphoma (FL) View DetailsA Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011) (NCT06136559)
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma View DetailsTesting Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study (NCT04269902)
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma View DetailsPublications
The following research publications from The Ottawa Hospital are pulled from PubMed, with publication date of 2020 or later. Note that PubMed is hosted by the U.S. National Library of Medicine and is only available in English.
Treatment of Multiple Myeloma: ASCO-Ontario Health (Cancer Care Ontario) Living Guideline.
2026-01-06 Go to publicationThe emerging promise of induced pluripotent stem cells in clinical studies: a systematic scoping review of the literature and registered clinical trials.
2026-01-01 Go to publicationThe impact of age on survival and excess mortality after autologous hematopoietic cell transplantation in newly diagnosed multiple myeloma patients.
2026-01-01 Go to publicationDefining the Limits of Pre-Transplant Risk Prediction in AML: Evidence from Machine Learning and Regression Models.
2025-12-31 Go to publicationReal world comparison of progression free survival and time to next therapy in 761 newly diagnosed multiple myeloma patients.
2025-12-18 Go to publication